XtalPi (2228.HK) and Laboratoires Pierre Fabre have entered a drug discovery partnership utilizing AI and robotics to target oncology and rare diseases, with financial terms including upfront and milestone payments.
XtalPi (2228.HK) announced a drug discovery collaboration with Laboratoires Pierre Fabre covering oncology, potentially dermatology and rare diseases, with an upfront payment plus milestones. However, the specific financial terms were not disclosed, so the deal's material value cannot be quantified; it validates the AI drug discovery platform but is a routine partnership announcement.
XtalPi Holdings (2228.HK) and Laboratoires Pierre Fabre announced a strategic collaboration on November 9, 2026, to develop novel small molecule therapeutics. The partnership leverages XtalPi's AI and robotics platform to target oncology, dermatology, and rare diseases, while Pierre Fabre manages clinical and commercial development.
The article says the agreement includes an upfront payment, multiple milestone payments and downstream economic participation, but the specific financial terms were not disclosed.
XtalPi will use its AI capabilities and robotics platform to design novel small molecule therapeutics against undisclosed targets in oncology, potentially dermatology, and rare diseases, while Pierre Fabre handles clinical and commercial development.